加科思药业集团有限公司（股票代码：01167）于2026年3月20日发布公告，披露公司在香港联交所场内回购普通股，相关事项已于当日完成。
\n\n 本次回购股份数量共计76,200股，占公司现有已发行股本约0.00969%。每股价格介乎6.66港元至6.70港元，总耗资约50.92万港元（约509,202港元）。回购完成后，公司已发行股本合计791,755,080股，其中786,119,580股为流通股份，5,635,500股为库藏股。
\n\n 公司指出，此次回购基于2025年6月10日通过的股份回购授权。截至目前，公司已根据该项授权累计回购2,615,700股。公司进一步确认，本次行动已遵守香港联交所上市规则及相关法规的要求。
\n\n 公告由公司董事王晓洁签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.